CAMBRIDGE, Mass., Aug. 29 /PRNewswire-FirstCall/ -- Biopure Corporation
(Nasdaq: BPUR) today announced the appointment of Guido J. Neels to the
company's board of directors. Neels brings to the board over 30 years of
professional management experience, including 23 years in the medical
industry.
Since mid 2004, Neels has served as chief operating officer of Guidant
Corporation, a world leader in the development of cardiovascular medical
products. He is responsible for the global operations of Guidant's four
operating units: Cardiac Rhythm Management, Vascular Intervention, Cardiac
Surgery, and Endovascular Solutions. From December 2002 to July 2004, he was
group chairman, Office of the President, responsible for worldwide sales
operations, corporate communications, corporate marketing, investor relations
and government relations. In January 2000, he was named president, Europe,
Middle East, Africa and Canada. He previously served as vice president of
global marketing for Vascular Intervention and as managing director for German
and Central European operations.
From 1982 until Guidant was spun off as an independent public company from
Eli Lilly and Co. in 1994, Neels held various general management and sales and
marketing positions at Lilly in Europe and the U.S. From 1972 to 1980, he
held positions in information technology, finance and manufacturing at Raychem
Corporation in Belgium and the U.S.
Neels is a director of the New England Healthcare Institute, a non-profit,
applied research health policy organization. He holds a M.B.A. degree from
Stanford University and a business engineering degree from the University of
Leuven in Belgium.
Biopure Corporation develops and manufactures intravenously administered
pharmaceuticals, called oxygen therapeutics, that deliver oxygen to the body's
tissues. The company is developing Hemopure(R) [hemoglobin glutamer -- 250
(bovine)], or HBOC-201, for a potential indication in cardiovascular ischemia
and, in collaboration with the U.S. Naval Medical Research Center, for an
out-of-hospital trauma indication. The product is approved in South Africa
for treating surgery patients who are acutely anemic and for eliminating,
delaying or reducing allogeneic red blood cell transfusions in these patients.
Hemopure has not been approved for sale in any other jurisdictions, including
the United States or the European Union. Biopure's veterinary product
Oxyglobin(R) [hemoglobin glutamer -- 200 (bovine)], or HBOC-301, the only
oxygen therapeutic approved by the U.S. Food and Drug Administration and the
European Commission, is indicated for the treatment of anemia in dogs.
Contact: Douglas Sayles
Biopure Corporation
(617) 234-6826
IR@biopure.com
SOURCE Biopure Corporation
 back to top
Related links:
http://www.biopure.com
Company News On-Call:
http://www.prnewswire.com/comp/131224.html
CONTACT:
Douglas Sayles of Biopure Corporation,
+1-617-234-6826, IR@biopure.com
|
